Oncotelic Therapeutics Expands Global Patent Protection for OT-101 TGF-β Antisense Therapy Across CNS and Neurology Applications
核心洞察
Oncotelic Therapeutics (搜索) and Sapu Bioscience (搜索) secured patent claims for OT-101 in Parkinson's Disease (搜索) treatment in Australia, including CNS delivery routes and sleep-related symptoms.
The companies obtained utility model patents in China and Germany for intracranial delivery devices supporting continuous CNS drug infusion through 2033.
OT-101, a TGF-β (搜索) antisense inhibitor, has established clinical foundation with prior trials in glioblastoma (搜索) and pancreatic cancers, now expanding into neurological applications.
Oncotelic Therapeutics (搜索) and Sapu Bioscience (搜索) have achieved significant milestones in expanding global intellectual property coverage for OT-101, their proprietary TGF-β (搜索) antisense therapeutic platform, strengthening protection across neurology, oncology, and central nervous system drug delivery applications.
Parkinson's Disease Patent Claims Secured in Australia
The companies received allowed patent claims in Australia explicitly covering OT-101 (SEQ ID NO:9) for treating Parkinson's Disease (搜索), including associated sleep-related symptoms such as excessive daytime sleepiness and insomnia. The granted claims encompass methods of treatment, manufacture-of-medicament claims, and protection for CNS delivery routes, including intrathecal injection or infusion and direct intracranial infusion.
CNS Delivery Device Patents Granted in China and Germany
Utility model patents titled "Device for Delivering Fluid Pharmaceutical Compositions by Intracranial Continuous Infusion" have been granted in China and Germany. The Chinese patent (announcement number CN 222693486 U) became effective April 1, 2025, while the German patent (DE 21 2023 000 368.6) extends through 2033. These grants provide device-level protection for continuous intracranial infusion technologies relevant to CNS therapeutics.
Clinical Foundation and Therapeutic Platform
OT-101 is a TGF-β (搜索) antisense inhibitor with multiple prior clinical trials conducted in various oncology indications including glioblastoma (搜索) and pancreatic cancers. The compound was also investigated for additional applications in Acute Respiratory Distress Syndrome (ARDS (搜索)) and COVID-19 (搜索)-related inflammatory conditions. Building on its established clinical foundation in oncology, Oncotelic is advancing OT-101 as a broader central nervous system-capable therapeutic platform, supported by targeted delivery technologies and expanded intellectual property coverage.
Multi-Layered Patent Strategy
Beyond these early issued patents, Oncotelic is building a multi-layered global "Patent Wall" around OT-101 designed to create durable exclusive barriers well beyond a single asset or indication. The company's intellectual property now spans therapeutic use, central nervous system delivery methods, device-enabled administration, dosing regimens, combination therapies, and biomarker-driven patient selection across oncology and neurology. This integrated structure makes replication or workarounds materially more complex, effectively protecting both the drug and how it is used.
Strategic Commercial Impact
These IP developments establish an integrated OT-101 CNS commercialization platform, combining therapeutic use claims in neurology with granted delivery-device protection. The company believes this expanded IP estate enhances OT-101's strategic value and supports future development, partnering, and commercialization efforts across oncology and neurological indications.
"OT-101 has a well-established clinical foundation, including prior clinical trials in multiple oncology indications, including glioblastoma (搜索), and these new IP milestones significantly expand its long-term potential," said Dr. Vuong Trieu, Chief Executive Officer of Oncotelic Therapeutics (搜索). "By securing Parkinson's Disease (搜索) claims in Australia and strengthening CNS delivery protection in China and Germany, we are building a globally defensible platform that supports both therapeutic use and delivery, while positioning the Company for strategic partnerships and long-term shareholder value creation."
Upcoming Presentations
The company will present at BIO-Europe Spring on March 23-25, 2026, where they will present data on OT-101 as well as their Deciparticle™ platform leading candidate: Sapu003 (搜索)-intravenous everolimus.
Oncotelic Therapeutics (搜索) is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products to address high-unmet-need cancers and rare pediatric indications. The company benefits from the robust portfolio of inventions created by CEO Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents.